Cellectricon Launches new Chip for Safety Pharmacology & hERG Studies
Gothenburg, Sweden: Cellectricon today announced the launch of the new Dynaflow (TM) Pro II System for safety pharmacology studies. The system comes with the newly developed DF-8 Pro II Chip successfully beta-tested for conducting GLP hERG studies by Swiss ion channel CRO bSys GmbH.
Developed for life scientists and drug discovery researchers, the Dynaflow System is an add-on to conventional patch-clamp and provides a solution to the current need for increased throughput and data quality in ion channel drug discovery. The system now comes with the newly developed Dynaflow 8-channel microfluidic chip (DF-8 Pro II Chip) designed for cumulative dose-response work and/or screening of slow acting compounds on non-desensitizing ion channels. The new DF-8 Pro II Chip has been beta-tested by the Swiss ion channel CRO bSys GmbH, who studied a variety of hERG inhibitory substances with results demonstrating the system performance as ideally suited for safety pharmacology studies.
Dr. Med. Daniel Konrad, CEO of bSys GmbH, said,”We have incorporated the Dynaflow system and the new DF-8 Pro II Chip into our cardiac safety assessment services. The system enabled us to perform standardized and reproducible GLP hERG studies of ion channels with outstanding data quality.”
“We’ve developed the new DF-8 Pro II Chip and Dynaflow Pro II Platform to meet the increasing demand for a system with safety pharmacology performance.” stated Mattias Karlsson, Ph.D., VP R&D at Cellectricon. “With the new Dynaflow Pro II System, and Dynaflow Microfluidic Chips (8-, 16- and 48-channels), Cellectricon now offers a complete product range for ion channel drug discovery.”
Cellectricon AB (Gothenburg, Sweden) invents and develops new types of functional cell-based screening devices for applications in drug discovery and basic research. The company utilizes state of the art interfaces to biological systems by employing novel microfabrication technologies and smart engineering solutions. This enables completely new types of assays and devices with superior performance characteristics and robustness. Cellectricon’s products are designed to enable substantial increases in productivity at the highest data quality. The company was formed in 2000 based on an extensive and solid patent portfolio within different areas such as high-throughput electrophysiology, microfluidics, microfabrication, and electroporation. Cellectricon is a privately held company and the main shareholders are InnovationsKapital, Investor Growth Capital and Karolinska Investment Fund.